Cargando…

Development of Apoptotic-Cell-Inspired Antibody–Drug Conjugate for Effective Immune Modulation

Background: Apoptotic cells’ phosphoserine (PS) groups have a significant immunosuppressive effect. They inhibit proinflammatory signals by interacting with various immune cells, including macrophages, dendritic cells, and CD4(+) cells. Previously, we synthesized PS-group-immobilized polymers and ve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Gyeongwoo, Iwase, Taishu, Matsumoto, Shunsuke, Nabil, Ahmed, Ebara, Mitsuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671176/ https://www.ncbi.nlm.nih.gov/pubmed/38003225 http://dx.doi.org/10.3390/ijms242216036

Ejemplares similares

Apoptotic Cell-Mimetic Polymers for Anti-Inflammatory Therapy
por: Ebara, Mitsuhiro
Publicado: (2019)

Temperature Responsive Polymer Conjugate Prepared by “Grafting from” Proteins toward the Adsorption and Removal of Uremic Toxin
por: Yoshihara, Erika, et al.
Publicado: (2022)

Preparation of Temperature-Responsive Antibody–Nanoparticles by RAFT-Mediated Grafting from Polymerization
por: Yoshihara, Erika, et al.
Publicado: (2022)

PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
por: Sau, Samaresh, et al.
Publicado: (2019)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014)

Application of Immuno-PET in Antibody–Drug Conjugate Development
por: Carmon, Kendra S., et al.
Publicado: (2018)

Antibody-drug conjugates: the clinical development in gastric cancer
por: Zhu, Yingze, et al.
Publicado: (2023)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
por: Song, Chi Hun, et al.
Publicado: (2023)

Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug Conjugates
por: Abdollahpour-Alitappeh, Meghdad, et al.
Publicado: (2017)

Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors
por: Murai, Aiko, et al.
Publicado: (2020)

ACCELERATING THE DEVELOPMENT OF NOVEL ANTIBODY-DRUG CONJUGATES THROUGH SITE-SPECIFIC CONJUGATION METHODS
por: Ouyang, An, et al.
Publicado: (2023)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Characterization of human anti-EpCAM antibodies for developing an antibody–drug conjugate
por: Satofuka, Hiroyuki, et al.
Publicado: (2023)

Development of Antibody–Drug Conjugates Using DDS and Molecular Imaging
por: Yasunaga, Masahiro, et al.
Publicado: (2017)

Bioprocess development of antibody-drug conjugate production for cancer treatment
por: Ou, Jianfa, et al.
Publicado: (2018)

Uncovering therapeutic opportunities in the clinical development of antibody‐drug conjugates
por: Nieto‐Jiménez, Cristina, et al.
Publicado: (2023)

Design and Synthesis of Pro-Apoptotic Compounds Inspired by Diatom Oxylipins
por: Romano, Giovanna, et al.
Publicado: (2013)

Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation
por: Cini, Elena, et al.
Publicado: (2018)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation
por: Christie, R. James, et al.
Publicado: (2017)

Quantitative pharmacology in antibody-drug conjugate development: armed antibodies or targeted small molecules?
por: Nessler, Ian, et al.
Publicado: (2018)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Antibody-Drug Conjugates: Possibilities and Challenges
por: Nejadmoghaddam, Mohammad-Reza, et al.
Publicado: (2019)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates: The Last Decade
por: Joubert, Nicolas, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Antibody-drug conjugates: Present and future
por: Beck, Alain, et al.
Publicado: (2013)

Antibody–Drug Conjugate to Treat Meningiomas
por: Chen, Kai, et al.
Publicado: (2021)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Mechanisms of Resistance to Antibody–Drug Conjugates
por: Abelman, Rachel Occhiogrosso, et al.
Publicado: (2023)

Mechanisms of Resistance to Antibody-Drug Conjugates
por: Khoury, Rita, et al.
Publicado: (2023)

Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
por: Chang, Hannah L., et al.
Publicado: (2023)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
por: Love, Elizabeth A., et al.
Publicado: (2019)

Development of and insights from systems pharmacology models of antibody‐drug conjugates
por: Lam, Inez, et al.
Publicado: (2022)

Payload diversification: a key step in the development of antibody–drug conjugates
por: Conilh, Louise, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_obhu8nvvbjjb5n37odo3u2s926